Inhalable nano into micro dry powders for ivacaftor delivery: the role of mannitol and cysteamine as mucus-active agents.

[1]  S. Jafari,et al.  Nano spray drying for encapsulation of pharmaceuticals , 2018, International journal of pharmaceutics.

[2]  G. Giammona,et al.  Mucus and Cell-Penetrating Nanoparticles Embedded in Nano-into-Micro Formulations for Pulmonary Delivery of Ivacaftor in Patients with Cystic Fibrosis. , 2018, ACS applied materials & interfaces.

[3]  G. Giammona,et al.  Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis. , 2017, Biomacromolecules.

[4]  C. Lehr,et al.  The role of mucus on drug transport and its potential to affect therapeutic outcomes☆ , 2017, Advanced drug delivery reviews.

[5]  C. Fiorica,et al.  Polymeric drug delivery micelle-like nanocarriers for pulmonary administration of beclomethasone dipropionate. , 2017, Colloids and surfaces. B, Biointerfaces.

[6]  P. Visca,et al.  Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[7]  A. Trapani,et al.  Realization of polyaspartamide-based nanoparticles and in vivo lung biodistribution evaluation of a loaded glucocorticoid after aerosolization in mice. , 2016, International journal of pharmaceutics.

[8]  G. Giammona,et al.  Improvements in Rational Design Strategies of Inulin Derivative Polycation for siRNA Delivery. , 2016, Biomacromolecules.

[9]  G. Giammona,et al.  Pegylated Polyaspartamide-Polylactide-Based Nanoparticles Penetrating Cystic Fibrosis Artificial Mucus. , 2016, Biomacromolecules.

[10]  F. Franconi,et al.  MRI-visible nanoparticles from hydrophobic gadolinium poly(ε-caprolactone) conjugates , 2015 .

[11]  C. Charrier,et al.  Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis , 2014, Orphanet Journal of Rare Diseases.

[12]  S. Doe,et al.  A new era in the treatment of cystic fibrosis. , 2014, Clinical medicine.

[13]  A. Prince,et al.  Cystic fibrosis: a mucosal immunodeficiency syndrome , 2012, Nature Medicine.

[14]  M. L. La Rotonda,et al.  Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Y. Yeo,et al.  Mannitol‐Guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model , 2011, Biotechnology and bioengineering.

[16]  S. Freedman,et al.  Cystic fibrosis , 2009, The Lancet.

[17]  F. Ratjen,et al.  Cystic fibrosis , 2003, The Lancet.

[18]  A S Verkman,et al.  Green fluorescent protein‐based halide indicators with improved chloride and iodide affinities , 2001, FEBS letters.

[19]  Y. Pan,et al.  The use of fluorescamine as a detection reagent in protein microcharacterization. , 1989, Journal of biochemical and biophysical methods.

[20]  G. Giammona,et al.  Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. , 2017, Nanomedicine.